Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Cozzi-Lepri, A.; Noguera-Julian, M.; Di Giallonardo, F.; Schuurman, R.; Daumer, M.; Aitken, S.; Ceccherini-Silberstein, F.; D’Arminio Monforte, A.; Geretti, A.M.; Booth, C.L.; et al. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based art: A multicohort european case-control study using centralized ultrasensitive 454 pyrosequencing. J. Antimicrob. Chemother. 2015, 70, 930–940. [Google Scholar] [CrossRef] [PubMed]
- Li, J.Z.; Paredes, R.; Ribaudo, H.J.; Svarovskaia, E.S.; Metzner, K.J.; Kozal, M.J.; Hullsiek, K.H.; Balduin, M.; Jakobsen, M.R.; Geretti, A.M.; et al. Low-frequency HIV-1 drug resistance mutations and risk of nnrti-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011, 305, 1327–1335. [Google Scholar] [CrossRef] [PubMed]
- Wittkop, L.; Gunthard, H.F.; de Wolf, F.; Dunn, D.; Cozzi-Lepri, A.; de Luca, A.; Kucherer, C.; Obel, N.; von Wyl, V.; Masquelier, B.; et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (eurocoord-chain joint project): A european multicohort study. Lancet Infect. Dis. 2011, 11, 363–371. [Google Scholar] [CrossRef]
- Wensing, A.M.; Calvez, V.; Gunthard, H.F.; Johnson, V.A.; Paredes, R.; Pillay, D.; Shafer, R.W.; Richman, D.D. 2017 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 2017, 24, 132–133. [Google Scholar] [PubMed]
- Rhee, S.Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.; Aghokeng, A.F.; et al. Correction: Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient- and sequence-level meta-analysis. PLoS Med. 2015, 12, e1001845. [Google Scholar] [CrossRef] [PubMed]
- Rhee, S.Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; Rinke de Wit, T.F.; Aghokeng, A.F.; et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient- and sequence-level meta-analysis. PLoS Med. 2015, 12, e1001810. [Google Scholar] [CrossRef] [Green Version]
- Balode, D.; Westman, M.; Kolupajeva, T.; Rozentale, B.; Albert, J. Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia. J. Med. Virol. 2010, 82, 2013–2018. [Google Scholar] [CrossRef] [PubMed]
- SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008, 22, 625–635. [Google Scholar] [CrossRef]
- Hofstra, L.M.; Sauvageot, N.; Albert, J.; Alexiev, I.; Garcia, F.; Struck, D.; Van de Vijver, D.A.; Asjo, B.; Beshkov, D.; Coughlan, S.; et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin. Infect. Dis. 2016, 62, 655–663. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wensing, A.M.; van de Vijver, D.A.; Angarano, G.; Asjo, B.; Balotta, C.; Boeri, E.; Camacho, R.; Chaix, M.L.; Costagliola, D.; De Luca, A.; et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J. Infect. Dis. 2005, 192, 958–966. [Google Scholar] [CrossRef] [PubMed]
- Castor, D.; Low, A.; Evering, T.; Karmon, S.; Davis, B.; Figueroa, A.; LaMar, M.; Garmon, D.; Mehandru, S.; Markowitz, M. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York city. J. Acquir. Immune Defic. Syndr. 2012, 61, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Boden, D.; Hurley, A.; Zhang, L.; Cao, Y.; Guo, Y.; Jones, E.; Tsay, J.; Ip, J.; Farthing, C.; Limoli, K.; et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282, 1135–1141. [Google Scholar] [CrossRef] [PubMed]
- Brenner, B.G.; Roger, M.; Moisi, D.D.; Oliveira, M.; Hardy, I.; Turgel, R.; Charest, H.; Routy, J.P.; Wainberg, M.A. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008, 22, 2509–2515. [Google Scholar] [CrossRef] [PubMed]
- Toni, T.A.; Asahchop, E.L.; Moisi, D.; Ntemgwa, M.; Oliveira, M.; Masquelier, B.; Brenner, B.G.; Wainberg, M.A. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob. Agents Chemother. 2009, 53, 1670–1672. [Google Scholar] [CrossRef] [PubMed]
- Brenner, B.G.; Roger, M.; Routy, J.P.; Moisi, D.; Ntemgwa, M.; Matte, C.; Baril, J.G.; Thomas, R.; Rouleau, D.; Bruneau, J.; et al. High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 2007, 195, 951–959. [Google Scholar] [CrossRef] [PubMed]
- Paraskevis, D.; Kostaki, E.; Magiorkinis, G.; Gargalianos, P.; Xylomenos, G.; Magiorkinis, E.; Lazanas, M.; Chini, M.; Nikolopoulos, G.; Skoutelis, A.; et al. Prevalence of drug resistance among HIV-1 treatment-naïve patients in Greece during 2003–2015: Transmitted drug resistance is due to onward transmissions. Infect. Genet. Evol. 2017, 54, 183–191. [Google Scholar] [CrossRef] [PubMed]
- Paraskevis, D.; Nikolopoulos, G.; Tsiara, C.; Paraskeva, D.; Antoniadou, A.; Lazanas, M.; Gargalianos, P.; Psychogiou, M.; Malliori, M.; Kremastinou, J.; et al. HIV-1 outbreak among injecting drug users in Greece, 2011: A preliminary report. Euro Surveill. 2011, 16, 19962. [Google Scholar] [CrossRef] [PubMed]
- Drummond, A.J.; Suchard, M.A.; Xie, D.; Rambaut, A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol. Biol. Evol. 2012, 29, 1969–1973. [Google Scholar] [CrossRef] [PubMed]
- Bouckaert, R.; Heled, J.; Kuhnert, D.; Vaughan, T.; Wu, C.H.; Xie, D.; Suchard, M.A.; Rambaut, A.; Drummond, A.J. BEAST 2: A software platform for bayesian evolutionary analysis. PLoS Comput. Biol. 2014, 10, e1003537. [Google Scholar] [CrossRef] [PubMed]
- Stadler, T.; Kuhnert, D.; Bonhoeffer, S.; Drummond, A.J. Birth-death skyline plot reveals temporal changes of epidemic spread in HIV and hepatitis C virus (HCV). Proc. Natl. Acad. Sci. USA 2013, 110, 228–233. [Google Scholar] [CrossRef] [PubMed]
- Paraskevis, D.; Paraschiv, S.; Sypsa, V.; Nikolopoulos, G.; Tsiara, C.; Magiorkinis, G.; Psichogiou, M.; Flampouris, A.; Mardarescu, M.; Niculescu, I.; et al. Enhanced HIV-1 surveillance using molecular epidemiology to study and monitor HIV-1 outbreaks among intravenous drug users (IDUS) in Athens and Bucharest. Infect. Genet. Evol. 2015, 35, 109–121. [Google Scholar] [CrossRef] [PubMed]
- Yang, W.L.; Kouyos, R.D.; Boni, J.; Yerly, S.; Klimkait, T.; Aubert, V.; Scherrer, A.U.; Shilaih, M.; Hinkley, T.; Petropoulos, C.; et al. Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. PLoS Pathog. 2015, 11, e1004722. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- European AIDS Clinical Society. Guidelines, version 8.2; European AIDS Clinical Society: Brussels, Belgium, 2017. [Google Scholar]
- Antoniadou, Z.A.; Kousiappa, I.; Skoura, L.; Pilalas, D.; Metallidis, S.; Nicolaidis, P.; Malisiovas, N.; Kostrikis, L.G. Short communication: Molecular epidemiology of HIV type 1 infection in northern Greece (2009–2010): Evidence of a transmission cluster of HIV type 1 subtype a1 drug-resistant strains among men who have sex with men. AIDS Res. Hum. Retrovir. 2014, 30, 225–232. [Google Scholar] [CrossRef] [PubMed]
- Drescher, S.M.; von Wyl, V.; Yang, W.L.; Boni, J.; Yerly, S.; Shah, C.; Aubert, V.; Klimkait, T.; Taffe, P.; Furrer, H.; et al. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the swiss HIV cohort study. Clin. Infect. Dis. 2014, 58, 285–294. [Google Scholar] [CrossRef] [PubMed]
- Mbisa, J.L.; Fearnhill, E.; Dunn, D.T.; Pillay, D.; Asboe, D.; Cane, P.A. Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom. Clin. Infect. Dis. 2015, 61, 829–836. [Google Scholar] [CrossRef] [PubMed]
- Mourad, R.; Chevennet, F.; Dunn, D.T.; Fearnhill, E.; Delpech, V.; Asboe, D.; Gascuel, O.; Hue, S. A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK. AIDS 2015, 29, 1917–1925. [Google Scholar] [CrossRef] [PubMed]
- Theys, K.; Van Laethem, K.; Gomes, P.; Baele, G.; Pineda-Pena, A.C.; Vandamme, A.M.; Camacho, R.J.; Abecasis, A.B. Sub-epidemics explain localized high prevalence of reduced susceptibility to rilpivirine in treatment-naive HIV-1-infected patients: Subtype and geographic compartmentalization of baseline resistance mutations. AIDS Res. Hum. Retrovir. 2016, 32, 427–433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Local Transmission Network | Number of Individuals | tMRCA 1 (Median; 95% HPD 2) | Re 3 (Maximum Value of Median) | CV 4 (Median; 95% HPD) |
---|---|---|---|---|
K103N | 48 | 2007 (2004–2009) | 2.8 | 0.25 (0.00002–0.68) |
E138A_1 | 22 | 1995 (1991–1999) | 2.1 | 1.10 (0.57–1.72) |
E138A_2 | 38 | 1996 (1989–2000) | 1.8 | 0.73 (0.47–1.04) |
E138A_3 | 50 | 1997 (1991–2001) | 2.0 | 0.84 (0.48–1.24) |
E138A_4 | 38 | 2004 (2000–2007) | 2.5 | 0.58 (0.20–0.95) |
Local Transmission Networks | ||||||
---|---|---|---|---|---|---|
K103N (N, %) | E138A_1 (N, %) | E138A_2 (N, %) | E138A_3 (N, %) | E138A_4 (N, %) | p-value | |
Number of individuals | 48 (24.5) | 22 (11.2) | 38 (19.4) | 50 (25.5) | 38 (19.4) | |
Gender | 0.159 | |||||
Male | 48 (100.0) | 21 (95.5) | 36 (94.7) | 50 (100.0) | 37 (97.4) | |
Female | 0 (0.0) | 1 (4.5) | 2 (5.3) | 0 (0.0) | 1 (2.6) | |
Risk group | 0.046 | |||||
MSM 1 | 35 (72.9) | 13 (59.1) | 24 (63.2) | 39 (78.0) | 32 (84.2) | |
PWID 2 | 1 (2.1) | 0 (0.0) | 1 (2.6) | 3 (6.0) | 1 (2.6) | |
MSW 3 | 1 (2.1) | 5 (22.7) | 5 (13.2) | 3 (6.0) | 0 (0.0) | |
Unknown | 11 (22.9) | 4 (18.2) | 8 (21.0) | 5 (10.0) | 5 (13.2) | |
Nationality | 0.020 | |||||
Hellenic | 21 (43.8) | 12 (54.6) | 27 (71.1) | 37 (74.0) | 21 (55.3) | |
Non Hellenic | 2 (4.2) | 0 (0.0) | 3 (7.9) | 1 (2.0) | 1 (2.6) | |
Unknown | 25 (52.0) | 10 (45.4) | 8 (21.0) | 12 (24.0) | 16 (42.1) |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Paraskevis, D.; Kostaki, E.; Gargalianos, P.; Xylomenos, G.; Lazanas, M.; Chini, M.; Skoutelis, A.; Papastamopoulos, V.; Paraskeva, D.; Antoniadou, A.; et al. Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health. Genes 2017, 8, 322. https://doi.org/10.3390/genes8110322
Paraskevis D, Kostaki E, Gargalianos P, Xylomenos G, Lazanas M, Chini M, Skoutelis A, Papastamopoulos V, Paraskeva D, Antoniadou A, et al. Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health. Genes. 2017; 8(11):322. https://doi.org/10.3390/genes8110322
Chicago/Turabian StyleParaskevis, Dimitrios, Evangelia Kostaki, Panagiotis Gargalianos, Georgios Xylomenos, Marios Lazanas, Maria Chini, Athanasios Skoutelis, Vasileios Papastamopoulos, Dimitra Paraskeva, Anastasia Antoniadou, and et al. 2017. "Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health" Genes 8, no. 11: 322. https://doi.org/10.3390/genes8110322